BioCentury
ARTICLE | Company News

Management tracks: Orchard, Black Diamond, ALK-Abelló, Menarini, Imvax, Rallybio, Milestone, MaaT and more

September 13, 2019 10:46 PM UTC

Jason Meyenburg has left Orchard Therapeutics plc (NASDAQ:ORTX) as CCO to become CEO of ophthalmic disease company Gemini Therapeutics Inc. (Cambridge, Mass.). Orchard President and CEO Mark Rothera will assume global commercial leadership responsibilities in the interim while the gene therapy company searches for a permanent successor.

Cancer company Black Diamond Therapeutics Inc. (Cambridge, Mass.) hired Thomas Leggett as CFO. Leggett was CFO of Axcella Health Inc. (NASDAQ:AXLA), where he helped the company raise $156 million across three financings including an IPO on NASDAQ (see “Cortexyme’s First-day Pop Leads IPO Quartet Amid Choppy Market”)...